1. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC);Amin;J. Clin. Oncol.,2014
2. Genetic and epigenetic alterations during renal carcinogenesis;Arai;Int. J. Clin. Exp. Pathol.,2010
3. Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy;Bylicki;Ann. Oncol.,2015
4. Common Terminology Criteria for Adverse Events (CTCAE) , version 4.03. 2016; https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
5. Cabozantinib versus everolimus in advanced renal-cell carcinoma;Choueiri;N. Engl. J. Med.,2015